Hennion & Walsh Asset Management Inc. Grows Stock Holdings in Johnson & Johnson $JNJ

Hennion & Walsh Asset Management Inc. lifted its position in shares of Johnson & Johnson (NYSE:JNJ) by 6.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 41,136 shares of the company’s stock after purchasing an additional 2,382 shares during the period. Hennion & Walsh Asset Management Inc.’s holdings in Johnson & Johnson were worth $8,513,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the business. New England Professional Planning Group Inc. bought a new position in Johnson & Johnson during the 4th quarter valued at approximately $202,000. Thompson Investment Management Inc. grew its position in shares of Johnson & Johnson by 0.4% in the 4th quarter. Thompson Investment Management Inc. now owns 49,245 shares of the company’s stock worth $10,191,000 after buying an additional 191 shares during the last quarter. Enterprise Financial Services Corp increased its stake in shares of Johnson & Johnson by 0.7% during the fourth quarter. Enterprise Financial Services Corp now owns 8,739 shares of the company’s stock valued at $1,809,000 after buying an additional 61 shares during the period. Beacon Investment Advisory Services Inc. raised its holdings in shares of Johnson & Johnson by 2.2% during the fourth quarter. Beacon Investment Advisory Services Inc. now owns 114,250 shares of the company’s stock valued at $23,644,000 after acquiring an additional 2,419 shares in the last quarter. Finally, Conrad Siegel Investment Advisors Inc. purchased a new stake in Johnson & Johnson in the fourth quarter worth $204,000. 69.55% of the stock is owned by institutional investors.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Royalty Pharma agreed to co?fund J&J’s autoimmune candidate JNJ?4804 with up to $500M, accelerating development while sharing cost/risk — a near?term financing boost that strengthens J&J’s immunology story and could materially de?risk future revenue upside. Royalty Pharma and J&J partner to develop autoimmune treatment
• Positive Sentiment: J&J’s recently approved oral psoriasis drug ICOTYDE showed durable 52?week efficacy and near?placebo safety in Phase 3/ICONIC data — a potential meaningful new product launch that bolsters immunology growth expectations. Will ICOTYDE’s First?in?Class Oral Psoriasis Launch Redefine J&J’s Immunology Narrative?
• Positive Sentiment: Market coverage frames the JNJ?4804 funding pact and other immunology moves as adding heft to J&J’s growth pipeline — positive sentiment for medium?term revenue prospects. Johnson & Johnson’s JNJ-4804 Deal Adds Weight To Immunology Story
• Positive Sentiment: An analyst shop (RBC) reaffirmed an outperform rating and set a $255 price target, signaling buy?side support and limited near?term upside capture by bulls. Benzinga: RBC Outperform, $255 PT
• Positive Sentiment: J&J presented encouraging randomized Phase 2 data (CONVERGE) for a radiotherapy?adjunct asset (NBTXR3/JNJ?1900) at a major conference — supportive for oncology pipeline valuation. NANOBIOTIX Announces Presentation of First Data
• Neutral Sentiment: Valuation and dividend analyses are being debated: some quant work questions whether JNJ remains undervalued after the rally, while other pieces emphasize its dividend?king status and defensive appeal — these shape investor positioning but don’t change fundamentals immediately. Seeking Alpha: Is the Stock Still Undervalued?
• Neutral Sentiment: Macro risk?off moves and a broader market rally (U.S. geopolitical headlines) have lifted many stocks; J&J’s low beta/dividend profile makes it a common safe?haven trade in volatile sessions. Dow Jones Futures: Market Soars As Trump Signals Iran War Exit
• Negative Sentiment: Media pieces (including commentary from Jim Cramer) continue to flag past “free fall” volatility and ongoing litigation exposures, which remain an overhang on sentiment and could cap multiple expansion until legal clarity improves. Jim Cramer Highlights J&J Stock’s Free Fall and Rise

Insiders Place Their Bets

In other news, EVP Timothy Schmid sold 1,322 shares of the business’s stock in a transaction on Friday, February 20th. The stock was sold at an average price of $245.66, for a total value of $324,762.52. Following the completion of the transaction, the executive vice president owned 25,447 shares in the company, valued at $6,251,310.02. The trade was a 4.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Vanessa Broadhurst sold 6,197 shares of the company’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total value of $1,508,287.83. Following the transaction, the executive vice president directly owned 23,003 shares in the company, valued at approximately $5,598,700.17. The trade was a 21.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 30,142 shares of company stock valued at $7,360,528. Corporate insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the stock. Scotiabank reiterated an “outperform” rating on shares of Johnson & Johnson in a report on Thursday, January 22nd. Wall Street Zen cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Wells Fargo & Company lifted their target price on shares of Johnson & Johnson from $230.00 to $240.00 and gave the company an “overweight” rating in a research note on Thursday, January 22nd. Weiss Ratings reiterated a “buy (b)” rating on shares of Johnson & Johnson in a research report on Wednesday, January 28th. Finally, TD Cowen raised their price objective on shares of Johnson & Johnson from $222.00 to $250.00 and gave the stock a “buy” rating in a report on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have given a Hold rating to the company. According to MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average target price of $236.91.

Johnson & Johnson Trading Up 0.8%

Shares of NYSE JNJ opened at $244.48 on Wednesday. The firm’s 50 day moving average price is $238.40 and its 200-day moving average price is $211.86. Johnson & Johnson has a 52-week low of $141.50 and a 52-week high of $251.71. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.77 and a current ratio of 1.03. The company has a market cap of $588.86 billion, a PE ratio of 22.12, a P/E/G ratio of 2.40 and a beta of 0.34.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Saturday, January 31st. The company reported $2.46 earnings per share for the quarter. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.04%. The company had revenue of $24.28 billion during the quarter. On average, equities research analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th were issued a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, February 24th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.1%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 47.06%.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.